Visit Contract Pharma
at Booth #1921

PPD Adds New Therapeutic Area Professionals


Expands experience in neuroscience, hematology/oncology, rare diseases and pediatrics

PPD’s appointment of Amy Chappell, M.D., and Alberto Lledó, M.D., Ph.D., in neuroscience; Timothy Miller, M.D., in rare diseases and pediatrics; and Konstantin Stoitchkov, M.D., Ph.D., in hematology/oncology strengthens PPD’s team of therapeutic area professionals with product development and commercialization experience.
Amy Chappell, M.D., has significant experience designing and implementing neuroscience clinical trials, first with Eli Lilly and Co. for 25 years and then as a consultant to companies such as Convergence Pharma, Biogen, Advicenne, Flexion and Lundbeck. Dr. Chappell is board certified in neurology (child) and lifestyle medicine. Her therapeutic area expertise is focused on nervous system disorders (Alzheimer’s disease, multiple sclerosis, pain, migraine, amyotrophic lateral sclerosis or ALS, Parkinson’s disease and epilepsy).
Alberto Lledó, M.D., Ph.D., is a board-certified neurologist with additional certification in neuroimmunology. His neuroscience therapeutic area expertise includes work with Parkinson’s disease, multiple sclerosis, pain, diabetic neuropathy, chronic pain, migraine, epilepsy, restless leg syndrome and Alzheimer’s disease. Before accepting his current role, Dr. Lledó worked with PPD as a consultant and executive director in global product development. Prior to that, he held roles as a neurology consultant and chief medical officer for Canbex Therapeutics, where he helped develop a new molecule for the symptomatic treatment of spasticity in multiple sclerosis patients.
Timothy Miller, M.D., is a board-certified, fellowship-trained, neuromuscular neurologist with more than a decade of increasing leadership experience in the biotechnology industry, as well as a solid background in academia at several institutions. He has focused his clinical and research work predominantly in the areas of pediatrics and rare neuromuscular and genetic diseases. He joined PPD from Sanofi Genzyme, where he served as medical director, senior medical director, global medical director, and vice president and head of medical affairs for North America rare diseases. Dr. Miller has a broad range of clinical and pharmaceutical expertise including rare genetic diseases, and rare and common neurologic, hematological and muscular conditions.
Konstantin Stoitchkov, M.D., Ph.D., has more than 25 years of experience in both clinical practice and research. His oncology and hematology experience includes treating patients with different types of hematological malignancies and solid tumors with surgery, chemotherapy, targeted immune and vaccine therapy, bone marrow transplantation and in clinical trials. He joined PPD from Terumo Europe, where he was medical director of oncology and responsible for the department of medical affairs.

“As the drug development process continues to become more complex, our clients are looking to PPD to provide medical and scientific expertise and strategic direction that extend far beyond traditional clinical trial implementation,” said Rob Dow, who, as chief medical officer, oversees PPD’s therapeutic areas. “These experts have held senior leadership roles in various capacities in the life sciences industry, providing them with a wide range of experience that offers significant strategic value to our clients.”